<DOC>
	<DOCNO>NCT00213993</DOCNO>
	<brief_summary>The objective study evaluate effectiveness antiperspirant prevent attenuate severity palmer-plantar erythrodysesthesia associate Food Drug Administration ( FDA ) -approved dos capecitabine . The hypothesis cytotoxic compound sweat prevent deposited skin cause chronic toxicity .</brief_summary>
	<brief_title>Topical Antiperspirant Hand-Foot Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<criteria>Has previously receive regimen include 5fluorouracil &gt; 18 year old No known allergy intolerance Ban Unscented RollOn Antiperspirant &lt; 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>